All In Biotech

Drug Trial Radar · NCT05311085

Cytisine and E-cigarettes With Supportive Text-messaging for Smoking Cessation (Cess@Tion)

Cytisine and E-cigarettes With Supportive Text-messaging for Smoking Cessation

Last checked: Nov 20, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 807 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

807

Actual

Start

May 5, 2022

Primary completion

May 2, 2024

Study completion Jul 26, 2024

Sponsor

Lead sponsor
University of Auckland, New ZealandAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This research focuses on maximizing the benefits of proven smoking cessation interventions to support people who smoke to quit, as part of the strategy to help New Zealand become smoke-free. A large, pragmatic community-based clinical trial is planned which draws on 15 years of smoking cessation research undertaken by the study team. This research has shown that both cytisine and nicotine e-cigarettes are more effective than nicotine replacement therapy at helping people to quit smoking, and are more acceptable to users. New Zealand research has also shown that text-messages offering advice and support around quitting smoking are highly effective and acceptable. The planned trial will test whether using cytisine and nicotine e-cigarettes together will help more New Zealanders to quit smoking long-term, compared to using cytisine alone or nicotine e-cigarettes alone. Participants in all three groups will also receive smoking cessation text-messaging behavioral support.

Conditions

  • Smoking Cessation

Interventions

  • CytisineDrug

    Standard dosing of: * days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day) * days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five. * days 13-16: one tablet every three hours (four tablets/day) * days 17-20: one tablet every 4-5 hours (three tablets/day) * days 21-25: one tablet every six hours (two tablets/day) Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)

  • Nicotine delivered via an e-cigaretteDrug

    Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco

  • Cytisine plus nicotine delivered via an e-cigaretteCombination product

    Cytisine: Standard dosing of: * days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day) * days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five. * days 13-16: one tablet every three hours (four tablets/day) * days 17-20: one tablet every 4-5 hours (three tablets/day) * days 21-25: one tablet every six hours (two tablets/day) Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day) Nicotine e-cigarette: Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with verified continuous smoking abstinenceTime frame: Six months post-quit date

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institute for Health Innovation, School of Population Health, Faculty of Medical and Health Sciences, University of Auckland

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.